197 related articles for article (PubMed ID: 14648660)
21. An evaluation of ductal carcinoma in-situ of breast and its correlation with the grade of associated invasive component.
Konar K; Chatterjee U; Dutta SK
Indian J Pathol Microbiol; 2001 Jul; 44(3):297-300. PubMed ID: 12024916
[TBL] [Abstract][Full Text] [Related]
22. Concordant loss of fragile gene expression early in breast cancer development.
Guler G; Uner A; Guler N; Han SY; Iliopoulos D; McCue P; Huebner K
Pathol Int; 2005 Aug; 55(8):471-8. PubMed ID: 15998374
[TBL] [Abstract][Full Text] [Related]
23. Ductal carcinoma in situ of the breast and heparanase-1 expression: a molecular explanation for more aggressive subtypes.
Maxhimer JB; Pesce CE; Stewart RA; Gattuso P; Prinz RA; Xu X
J Am Coll Surg; 2005 Mar; 200(3):328-35. PubMed ID: 15737842
[TBL] [Abstract][Full Text] [Related]
24. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast.
Wykoff CC; Beasley N; Watson PH; Campo L; Chia SK; English R; Pastorek J; Sly WS; Ratcliffe P; Harris AL
Am J Pathol; 2001 Mar; 158(3):1011-9. PubMed ID: 11238049
[TBL] [Abstract][Full Text] [Related]
25. A SAGE (serial analysis of gene expression) view of breast tumor progression.
Porter DA; Krop IE; Nasser S; Sgroi D; Kaelin CM; Marks JR; Riggins G; Polyak K
Cancer Res; 2001 Aug; 61(15):5697-702. PubMed ID: 11479200
[TBL] [Abstract][Full Text] [Related]
26. Frequent alterations of chromosome 1 in ductal carcinoma in situ of the breast.
Munn KE; Walker RA; Varley JM
Oncogene; 1995 Apr; 10(8):1653-7. PubMed ID: 7731721
[TBL] [Abstract][Full Text] [Related]
27. Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium.
Shim V; Gauthier ML; Sudilovsky D; Mantei K; Chew KL; Moore DH; Cha I; Tlsty TD; Esserman LJ
Cancer Res; 2003 May; 63(10):2347-50. PubMed ID: 12750248
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of MUC1 splice variants as prognostic markers in patients with ductal carcinoma in situ of the breast.
Schmid BC; Rudas M; Fabjani G; Speiser P; Kaserer K; Leodolter S; Zeillinger R
Oncol Rep; 2003; 10(6):1981-5. PubMed ID: 14534730
[TBL] [Abstract][Full Text] [Related]
29. Widespread chromosomal abnormalities in high-grade ductal carcinoma in situ of the breast. Comparative genomic hybridization study of pure high-grade DCIS.
Moore E; Magee H; Coyne J; Gorey T; Dervan PA
J Pathol; 1999 Mar; 187(4):403-9. PubMed ID: 10398098
[TBL] [Abstract][Full Text] [Related]
30. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
Subramaniam MM; Chan JY; Soong R; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
Breast Cancer Res Treat; 2009 Jan; 113(1):113-21. PubMed ID: 18256927
[TBL] [Abstract][Full Text] [Related]
31. Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma.
De Paepe B; Verstraeten VL; De Potter CR; Vakaet LA; Bullock GR
Histochem Cell Biol; 2001 Sep; 116(3):247-54. PubMed ID: 11685554
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion.
Asch HL; Winston JS; Edge SB; Stomper PC; Asch BB
Breast Cancer Res Treat; 1999 May; 55(2):179-88. PubMed ID: 10481945
[TBL] [Abstract][Full Text] [Related]
33. Chromosomal alterations associated with the transition from in situ to invasive breast cancer.
Ellsworth RE; Vertrees A; Love B; Hooke JA; Ellsworth DL; Shriver CD
Ann Surg Oncol; 2008 Sep; 15(9):2519-25. PubMed ID: 18622645
[TBL] [Abstract][Full Text] [Related]
34. The desmoplastic response to infiltrating breast carcinoma: gene expression at the site of primary invasion and implications for comparisons between tumor types.
Iacobuzio-Donahue CA; Argani P; Hempen PM; Jones J; Kern SE
Cancer Res; 2002 Sep; 62(18):5351-7. PubMed ID: 12235006
[TBL] [Abstract][Full Text] [Related]
35. Correlation between type and grade of ductal carcinoma in situ and concomitant invasive ductal carcinoma of the breast.
Rudnicka L; Stachura J
Pol J Pathol; 2000; 51(3):137-43. PubMed ID: 11247396
[TBL] [Abstract][Full Text] [Related]
36. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
37. Placental localization and expression of the cell death factors BNip3 and Nix in preeclampsia, intrauterine growth retardation and HELLP syndrome.
Stepan H; Leo C; Purz S; Höckel M; Horn LC
Eur J Obstet Gynecol Reprod Biol; 2005 Oct; 122(2):172-6. PubMed ID: 16219518
[TBL] [Abstract][Full Text] [Related]
38. Microdissection and SAGE as a combined tool to reveal gene expression in ductal carcinoma in situ of the breast.
Verlinden I; Janssens J; Raus J; Michiels L
Mol Carcinog; 2004 Dec; 41(4):197-206. PubMed ID: 15486950
[TBL] [Abstract][Full Text] [Related]
39. Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma.
Shin SJ; Simpson PT; Da Silva L; Jayanthan J; Reid L; Lakhani SR; Rosen PP
Am J Surg Pathol; 2009 Apr; 33(4):496-504. PubMed ID: 19047897
[TBL] [Abstract][Full Text] [Related]
40. Collagen gene expression in the neomatrix of carcinoma of the breast.
Wapnir IL; Southard H; Chen G; Friedman J; Boyd CD; Amenta PS
Invasion Metastasis; 1996; 16(6):308-16. PubMed ID: 9371230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
